Why “American Patients First” is likely to raise drug prices outside of the United States
Background: The Trump administration’s ‘American Patients First’ blueprint proposes to reduce drug prices in the USA by increasing drug prices abroad, ex USA. The possibility of the Trump administration to raise drug prices ex USA through legal action via the WTO and bilateral negotiations with fore...
Main Authors: | Monique Dabbous, Cyprien Milea, Steven Simoens, Clement François, Claude Dussart, Lylia Chachoua, Borislav Borissov, Mondher Toumi |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2019-01-01
|
Series: | Journal of Market Access & Health Policy |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/20016689.2019.1650596 |
Similar Items
-
President Trump’s prescription to reduce drug prices: from the campaign trail to American Patients First
by: Monique Dabbous, et al.
Published: (2019-01-01) -
Multilateral Organization vs. Bilateral Negotiations: A Case of the Trade-Related Aspects of Intellectual Property Rights (TRIPs)
by: Namhoon Kwon
Published: (2001-12-01) -
Reading EU trade policy from a multilateral perspective
by: Patricia Garcia-Duran, et al.
Published: (2014-12-01) -
THE RETREAT OF TRADE MULTILATERALISM AND THE ASSAULT OF PROTECTIONISM
by: Agnes Ghibuțiu
Published: (2018-07-01) -
Um balanço da reunião da OMC em Cancún
by: AMADO LUIZ CERVO
Published: (2011-08-01)